Blog
RSS FeedPosted by Michael Wonder on 21 Mar 2022
NICE recommends elosulfase alfa for routine NHS use for patients with rare life-limiting metabolic disorder
21 March 2022 - NICE has today published final draft guidance recommending elosulfase alfa (Vimizim; BioMarin) for routine use in ...
Posted by Michael Wonder on 16 Mar 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
16 March 2022 - NICE has published evidence-based recommendations on the use of dostarlimab (Jemperli) for the treatment of adults ...
Posted by Michael Wonder on 10 Mar 2022
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of solriamfetol hydrochloride (Sunosi) for the treatment ...
Posted by Michael Wonder on 10 Mar 2022
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of pitolisant hydrochloride for the treatment of ...
Posted by Michael Wonder on 10 Mar 2022
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
9 March 2022 - NICE has published evidence based recommendations on the use of pegcetacoplan (Aspaveli) for the treatment of ...
Posted by Michael Wonder on 09 Mar 2022
Dapagliflozin for treating chronic kidney disease
9 March 2022 - NICE has published evidence based recommendations on dapagliflozin propanediol monohydrate (Forxiga) for adults with chronic kidney ...
Posted by Michael Wonder on 09 Mar 2022
Empagliflozin for treating chronic heart failure with reduced ejection fraction
9 March 2022 - NICE has published evidence based recommendations on the use of empagliflozin (Jardiance) for the treatment of ...
Posted by Michael Wonder on 09 Mar 2022
NICE unable to provide guidance on a new use of lenalidomide
9 March 2022 - NICE is unable to make a recommendation on the use of lenalidomide for the treatment of patients ...
Posted by Michael Wonder on 03 Mar 2022
Over 500 people a year can access a new life extending lung cancer treatment after NICE recommends its use within the Cancer Drugs Fund
3 March 2022 - An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults ...
Posted by Michael Wonder on 25 Feb 2022
NICE draft guidance recommends tucatinib for advanced breast cancer
25 February 2022 - Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib ...
Posted by Michael Wonder on 24 Feb 2022
Once a day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
24 February 2022 - The 20th cancer treatment to go through the Cancer Drugs Fund following a period of managed access ...
Posted by Michael Wonder on 15 Feb 2022
NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance
15 February 2022 - Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related ...
Posted by Michael Wonder on 08 Feb 2022
NICE recommends new drug for people living with obesity
8 February 2022 - Thousands of people living with obesity are set to benefit from a new drug which has helped ...
Posted by Michael Wonder on 04 Feb 2022
First gene therapy for rare genetic neurodegenerative disorder in children, recommended in NICE draft guidance
4 February 2022 - Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment ...
Posted by Michael Wonder on 04 Feb 2022
Libmedly: world's 'most expensive' drug recommended for NHS use
4 February 2022 - The NHS has struck a confidential deal for what's thought to be the most expensive drug ...